New technique to speed up drug development

Scientists working at the European Molecular Biology Laboratory (EMBL) in Grenoble, France have developed a new technique that enables them to introduce up to 15 fluorescent markers to a mammalian cell in one go. They say their findings could help speed up drug development and screening. The study was funded in part by the P-CUBE (Protein production platforms) project, which has clinched EUR 6.6 million through the Research Infrastructures budget line of the EU's Seventh Framework Programme (FP7).

EMBL's Imre Berger previously developed a technique that allowed scientists to create the equivalent of a make-up brush that is applied only once and highlights different features simultaneously. So cells could be given fluorescent labels to mark various cellular components in different colours, for example blue for the nucleus, yellow for the tubulin (a component of the cell's scaffolding), red for the mitochondria, cyan for the membranes of vesicles called endosomes, and purple for the other membrane structures. This technology was created by Dr Berger as part of a method called MultiBac and used for expressing protein complexes in insect cells.

In this latest study, published in the journal Nature Communications, Dr Berger and Philipp Berger from the Paul Scherrer Institut (PSI) in Villigen, Switzerland joined forces to take this technology a step further, adopting the concept to mammalian cells like our own for the first time. This essentially involved rapidly engineering a single vector to deliver a theoretically unlimited number of foreign genes, to a cell.

To date, the scientists have successfully delivered up to 15 genes in this way. The protein encoded by each of those genes can carry a fluorescent label, so this makes multiple labelling much more efficient than previous methods. The new labelling technique for mammalian cells, called MultiLabel, could help make drug development and screening considerably faster, since it allows scientists to precisely label many cellular components involved in a given disease process and follow them all at the same time.

"The introduction of heterologous genetic information, particularly of multiple genes, into mammalian cells is a key technology in contemporary experimental biological research," the researchers said.

"The co-expression of fluorescently tagged sensors is required to simultaneously analyse multiple parameters in living cells and the co-expression of several proteins is necessary to manipulate cell fate in stem cell biology. Current technologies for multigene expression in mammalian cells are inefficient, inflexible and time-consuming."

The team explained that MultiLabel is "a novel and highly efficient modular plasmid-based eukaryotic expression system".

The P-CUBE project aims to provide greater, free access for European users to the most advanced techniques in cloning, expression, protein characterisation and crystallisation. To this end, the British and Swiss-based scientists involved in the project regularly share expertise to improve technologies and standardise procedures, with the ultimate aim of disseminating this expertise throughout Europe.

For more information, please visit:

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...